En severe combined NP treatment of advanced non-small cell lung cancer.docVIP

 PAGE \* MERGEFORMAT 3 En severe combined NP treatment of advanced non-small cell lung cancer [Keywords:] lung cancer non-small cell lung cancer Combined chemotherapy Endostar NP Program Lung cancer including small-cell lung cancer and non-small cell lung cancer (non  small cell lung cancer, NSCLC). Among them, non-small cell lung cancer has been diagnosed lung cancer accounts for about 80%, while 70% ~ 80% of patients diagnosed in the initial Already at the time into the late (IIIB locally advanced stage and distant metastasis Ⅳ ), loss of opportunity for surgical treatment . Despite a multi-disciplinary comprehensive treatment, lung cancer, the overall cure rate is still less than 10% [1]. The beginning of the 20th century, 70 years, Folkman first proposed such as malignant tumor growth and metastasis depend on the views of tumor angiogenesis [2,3], which began in tumor angiogenesis and vascular targeting therapy research. In which O’Reilly et al [4] found to be the most ideal endostatin, which not only inhibit tumor angiogenesis and tumor metastasis, so that tumor cell apoptosis, but does not produce drug resistance, toxic side-effects of light. I am being introduced endostatin antitumor agents Endostar combined NP treatment of advanced non-small cell lung cancer, 13 cases achieved good short-term effect, are reported below. A clinical data August 2006 ~ May 2008 in our hospital surgical treatment of advanced NSCLC tumors in 31 patients, were confirmed by pathology and clinical stage of the 1997 International Union Against Cancer (UICC) criteria for NSCLC. In which squamous cell carcinoma in 13 cases, adenocarcinoma 15 cases, adenosquamous carcinoma in 3 cases; entirely of newly diagnosed patients, Karnofsky score 70 to 100 points; have a measurable clinical observation or evaluation indicators; have the chest, liver, brain CT or MRI, serum tumor markers, etc.; blood count, liver and kidney function, blood glucose and ECG were normal; is expected to su